top of page

F1901: LEAD CANDIDATE FOR INTRATUMORAL IMMUNE-THERAPY IN VETERINARY MEDICINE

​​

“F1901 is indicated in canine oral solid tumors grade I to III such as melanoma and squamous cell carcinoma

  • F1901 is an innate immune system enhancer having great potential for targeting different types of cancer, and is set to become a blockbuster in immunotherapy.

  • F1901 mechanism of action has been extensively studied at Gustave Roussy.

  • In immunocompetent murine models, F1901 has been shown to:

    • Induce immunogenic tumor cell death and antitumor vaccination with a dose response effect

    • Enhance response to anti-PD1

  • Because of their similar biology and response to treatment, canine solid tumors may serve as a translational model for human cancer.

image_edited.png
bottom of page